Key result
Cotreatment with metformin (500 mg/kg) eliminated doxorubicin-induced biochemical, histopathological, and ultrastructural changes in a rat model of cardiotoxicity.
Why the study?
Does metformin cotreatment prevent doxorubicin-induced cardiotoxicity in a rat model?
Population
Rat model of doxorubicin (DOX)-induced cardiotoxicity
Comparison
Metformin (500 mg/kg) cotreatment vs Doxorubicin treatment alone
Design
Preclinical
Authors
Loading...
Metformin cotreatment prevented doxorubicin cardiotoxicity in rats; hypothesis-generating and requires clinical trials before any human application.
Does metformin cotreatment prevent doxorubicin-induced cardiotoxicity in a rat model?
Metformin cotreatment prevents doxorubicin-induced cardiotoxicity in a rat model by inhibiting oxidative stress and energy starvation, suggesting a potential cardioprotective strategy.
Ashour et al. (2012) studied Doxorubicin-induced cardiotoxicity. Metformin vs. Doxorubicin alone was evaluated on Biochemical, histopathological, and ultrastructural changes. Cotreatment with metformin (500 mg/kg) eliminated doxorubicin-induced biochemical, histopathological, and ultrastructural changes in a rat model of cardiotoxicity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: